Treatment of Non-Flare Ulcerative Colitis with Rectal Bleeding

Clinical Assessment and Treatment Selection

For patients with distal disease (proctitis or proctosigmoiditis), the American Gastroenterological Association recommends mesalamine suppositories 1g once daily as the preferred first-line treatment for proctitis 1, 2
The European Crohn’s and Colitis Organisation suggests that mesalamine enemas ≥1g daily are preferred for proctosigmoiditis extending beyond the rectum 1, 3
Topical mesalamine is superior to topical corticosteroids for inducing remission in patients with distal disease 3

The American Gastroenterological Association recommends that prednisolone should only be added after optimized mesalamine therapy has failed, specifically if rectal bleeding persists beyond 10-14 days despite appropriate mesalamine therapy 3
The European Crohn’s and Colitis Organisation suggests that prednisolone should be added if sustained relief from all symptoms has not been achieved after 40 days of appropriate 5-ASA therapy 3

The key principle is that mesalamine therapy (topical ± oral) is first-line, and prednisolone is reserved for mesalamine-refractory disease 1, 3
The American Gastroenterological Association recommends that combination therapy with oral mesalamine ≥2.4g/day PLUS mesalamine enema 1g daily is superior to either alone for extensive or left-sided disease 1, 3
The typical prednisolone dose when indicated is 40mg daily orally, as suggested by the Praxis Medical Insights 2

Mesalamine is the cornerstone first-line therapy for mild-to-moderate ulcerative colitis, effective for both induction and maintenance of remission, with efficacy that is dose-dependent and route-dependent based on disease location 4

For extensive mild-moderate UC, standard-dose oral mesalamine (2-3 grams/day) or diazo-bonded 5-ASA is strongly recommended over low-dose mesalamine (<2g/day), sulfasalazine, or no treatment 4, 5
Once-daily dosing is preferred over multiple daily doses to improve adherence, with comparable efficacy 4, 5
Adding rectal mesalamine to oral therapy is recommended, as combination therapy is superior to either alone 4, 5
For patients with suboptimal response to standard-dose therapy or moderate disease activity, escalate to high-dose mesalamine (>3 grams/day) combined with rectal mesalamine 4, 5

Consider escalating to immunosuppressive therapy for patients with corticosteroid-dependence or frequent courses of corticosteroids (≥1 course/year) 6, 7

Do not use low-dose mesalamine (<2g/day) - it is less effective than standard doses 4, 5
Do not use oral mesalamine alone for distal disease - rectal therapy is superior for proctitis and proctosigmoiditis 4, 5